Skip to content
HelpLine
1-800-298-2436
support@go2.org
General Questions
650-598-2857
info@go2.org
About
Research
Blog
Advocacy
For Professionals
Donate
Search for:
Search for:
Home
What is Lung Cancer
Symptoms
Diagnosis
Coping with Diagnosis
Types of Lung Cancer
Lung Cancer Staging
Second Opinions
Lung Cancer Facts
Risk & Early Detection
About Screening
Frequently Asked Questions
Screening Facts & Figures
Risk Factors
Screening Centers
Treatments & Side Effects
Biomarker Testing
Clinical Trials
Frequently Asked Questions About Clinical Trials
Treatment Options
Chemotherapy
Radiation
Surgery
Immunotherapy
Checkpoint Inhibitors
Vaccines
Molecular Tests and Biomarkers
Targeted Therapy
Drugs Targeting EGFR
Drugs Targeting ALK
Drugs Targeting ROS1
Drugs Targeting BRAF
Drugs Targeting KRAS
Drugs Targeting NTRK
Drugs Targeting MET
Drugs Targeting RET
Other Targeted Therapies
Clinical Trials
Ablation Therapy
Complementary and Alternative Medicine
Hospice Care
Palliative Care
Photodynamic Therapy
Centers of Excellence
Treatment Centers
Side Effect Management
Lung Cancer Stigma
Staying Healthy
Resources & Support
Our Services
HelpLine & Support
LungMATCH: Treatment Guidance
Phone Buddy
Financial and Other Resources
Support Group Network
Lung Cancer Living Room
Gathering HOPE
Patient Communities
Educational Materials
Download Educational Materials
The Living Room: A Lung Cancer Community of Courage
Online Store
Questions for Your Healthcare Team
Video Library
Get Involved
Ways to Give
Events
Your Support Makes An Impact
Lung Cancer Awareness
Share Your Story
Join the Lung Cancer Registry
Volunteer as a Phone Buddy
Become an Ambassador
Start a Fundraiser
Honor a Loved One
Search for:
Group_Stakeholder_Letter_NGSNCD-FINAL-1-31-2019
Bethany Johnson (GO2 for Lung Cancer)
2019-02-21T21:26:40-06:00
Group_Stakeholder_Letter_NGSNCD-FINAL-1-31-2019
Go to Top
